BioCentury
ARTICLE | Company News

Oncodesign, Sanofi deal

April 1, 2013 7:00 AM UTC

The companies partnered to identify and synthesize inhibitors of an undisclosed kinase from Sanofi involved in tissue protection and repair using Oncodesign's Nanocyclix medicinal chemistry technology. Sanofi, which will fund the initial phase of the deal, has the option to license exclusive rights to molecules resulting from the deal. The partners declined to disclose details. ...